{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T09:21:45Z","timestamp":1784366505468,"version":"3.55.0"},"reference-count":96,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,11,25]],"date-time":"2008-11-25T00:00:00Z","timestamp":1227571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2009,1]]},"abstract":"<jats:p>Accumulated understanding of the molecular pathways regulating cancer progression has led to the development of novel targeted therapies. Hepatocellular carcinoma (HCC) remains a highly lethal disease that is resistant to conventional cytotoxic chemotherapy and radiotherapy. Unlike conventional chemotherapy, molecular\u2010targeted agents offer the potential advantages of a relatively high therapeutic window and use in combination with other anticancer strategies without overlapping toxicity. It is hoped that these drugs will become valuable therapeutic tools within the multimodal approach to treating cancer. A recent clinical trial revealed an oral multikinase inhibitor, sorafenib, as the first agent that has demonstrated improved overall survival in patients with advanced HCC. The present review summarizes molecular abnormalities of HCC with a focus on clinical studies, and current status as well as problems of the targeted strategies for HCC. (<jats:italic>Cancer Sci <\/jats:italic>2009; 100: 1\u20138)<\/jats:p>","DOI":"10.1111\/j.1349-7006.2008.01006.x","type":"journal-article","created":{"date-parts":[[2008,11,25]],"date-time":"2008-11-25T23:24:19Z","timestamp":1227655459000},"page":"1-8","source":"Crossref","is-referenced-by-count":84,"title":["Molecularly targeted therapy for hepatocellular carcinoma"],"prefix":"10.1111","volume":"100","author":[{"given":"Shinji","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Arii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,1]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1934"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199903113401009"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.20456"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1067\/msy.2002.119495"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23175"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-006-0566-5"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.1"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.32535"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2005.11.012"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardiores.2004.12.002"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510230309"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1309\/FXNL-QTN1-94FH-AB3A"},{"key":"e_1_2_8_15_2","first-page":"13","article-title":"Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma","volume":"17","author":"Li XM","year":"1998","journal-title":"J Exp Clin Cancer Res"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510270613"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.56.11.854"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)00503-8"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.48.1.87"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(99)00074-9"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2000.2093"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI4891"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.284.5422.1994"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.04.035"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.06.022"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature04186"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1507"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1150224"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1443"},{"key":"e_1_2_8_30_2","first-page":"327","article-title":"In\u00a0vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet\u2010derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel DB","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"18","key":"e_1_2_8_31_2","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1200\/jco.2007.25.18_suppl.3546","article-title":"Assessment of safety and drug\u2010induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC).","volume":"25","author":"Faivre SJ","year":"2007","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_32_2","first-page":"2178","article-title":"PTK787\/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor\u2010induced responses and tumor growth after oral administration","volume":"60","author":"Wood JM","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-3462"},{"issue":"16","key":"e_1_2_8_34_2","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/jco.2005.23.16_suppl.4134","article-title":"Influence of hepatic dysfunction on safety, tolerability, and pharmacokinetics of PTK787\/ZK 222584 in patients with unresectable hepatocellular carcinoma (HCC)","volume":"23","author":"Koch I","year":"2005","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-4409"},{"key":"e_1_2_8_36_2","unstructured":"AlbertsSR MorlanBW KimGPet\u00a0al.NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC)\u2010interim review of toxicity.2007Gastrointestinal Cancer Symposium; 19\u201321 Jan 2007 Orlando FL USA. Abstract 186."},{"key":"e_1_2_8_37_2","first-page":"4152","article-title":"SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors","volume":"60","author":"Laird AD","year":"2000","journal-title":"Cancer Res"},{"issue":"18","key":"e_1_2_8_38_2","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1200\/jco.2006.24.18_suppl.4145","article-title":"New feasibility study design with hepatocellular carcinoma: A phase I\/II study of TSU\u201068, an oral angiogenesis inhibitor","volume":"24","author":"Kanai F","year":"2006","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032691"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1104819"},{"issue":"18","key":"e_1_2_8_41_2","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1200\/jco.2006.24.18_suppl.4144","article-title":"Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein.","volume":"24","author":"Schwartz JD","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18","key":"e_1_2_8_42_2","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1200\/jco.2007.25.18_suppl.4570","article-title":"Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring.","volume":"25","author":"Malka D","year":"2007","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.9130"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2005.10.018"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510280111"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.298.5593.522"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099314"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040938"},{"issue":"18","key":"e_1_2_8_49_2","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1200\/jco.2006.24.18_suppl.4143","article-title":"Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group's Study E1203.","volume":"24","author":"O'Dwyer PJ","year":"2006","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_50_2","first-page":"4838","article-title":"Induction of apoptosis and cell cycle arrest by CP\u2010358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase","volume":"57","author":"Moyer JD","year":"1997","journal-title":"Cancer Res"},{"key":"e_1_2_8_51_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.14.696"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22886"},{"issue":"18","key":"e_1_2_8_53_2","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1200\/jco.2006.24.18_suppl.4010","article-title":"Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2\/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC\u2010P) Trial","volume":"24","author":"Ramanathan RK","year":"2006","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_54_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199611000-00006"},{"key":"e_1_2_8_55_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.5906"},{"key":"e_1_2_8_56_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22829"},{"issue":"18","key":"e_1_2_8_57_2","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1200\/jco.2007.25.18_suppl.4598","article-title":"A phase II open\u2010label study of cetuximab in unresectable hepatocellular carcinoma: final results.","volume":"25","author":"Gruenwald V","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18","key":"e_1_2_8_58_2","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1200\/jco.2007.25.18_suppl.4594","article-title":"Gemcitabine, oxaliplatin (GEMOX) and cetuximab for treatment of hepatocellular carcinoma (HCC): results of the phase II study ERGO.","volume":"25","author":"Louafi S","year":"2007","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_59_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-06-0080"},{"key":"e_1_2_8_60_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-814151"},{"key":"e_1_2_8_61_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.24.14610"},{"key":"e_1_2_8_62_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260310"},{"key":"e_1_2_8_63_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119016"},{"key":"e_1_2_8_64_2","first-page":"3391","article-title":"Insulin receptor substrate\u20101 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor\u2010\u03b21 induced apoptosis","volume":"56","author":"Tanaka S","year":"1996","journal-title":"Cancer Res"},{"key":"e_1_2_8_65_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5249.665"},{"key":"e_1_2_8_66_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-05-0252"},{"key":"e_1_2_8_67_2","first-page":"8912","article-title":"A fully human monoclonal antibody to the insulin\u2010like growth factor I receptor blocks ligand\u2010dependent signaling and inhibits human tumor growth in\u00a0vivo","volume":"63","author":"Burtrum D","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_8_68_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/97.11.790"},{"key":"e_1_2_8_69_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22221"},{"key":"e_1_2_8_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(03)01077-8"},{"key":"e_1_2_8_71_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-005-2908-y"},{"key":"e_1_2_8_72_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206338"},{"key":"e_1_2_8_73_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1934"},{"key":"e_1_2_8_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00248-4"},{"key":"e_1_2_8_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2007.08.001"},{"key":"e_1_2_8_76_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210019"},{"key":"e_1_2_8_77_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.116"},{"key":"e_1_2_8_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2004.12.040"},{"key":"e_1_2_8_79_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI26322"},{"key":"e_1_2_8_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2005.04.014"},{"key":"e_1_2_8_81_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.11.030"},{"key":"e_1_2_8_82_2","first-page":"2638","article-title":"The proteasome inhibitor PS\u2010341 in cancer therapy","volume":"5","author":"Teicher BA","year":"1999","journal-title":"Clin Cancer Res"},{"issue":"15","key":"e_1_2_8_83_2","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1200\/jco.2004.22.90140.4089","article-title":"Phase I\/II trial of botrezomib in patients with unresectable hepatocellular carcinoma.","volume":"22","author":"Hegewisch\u2010Becker S","year":"2004","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gde.2006.12.008"},{"key":"e_1_2_8_85_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1502"},{"key":"e_1_2_8_86_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1489406"},{"key":"e_1_2_8_87_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2257"},{"key":"e_1_2_8_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2006.10.004"},{"key":"e_1_2_8_89_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.6011"},{"key":"e_1_2_8_90_2","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E04-10-0891"},{"key":"e_1_2_8_91_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200208092"},{"key":"e_1_2_8_92_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1003"},{"key":"e_1_2_8_93_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1964"},{"key":"e_1_2_8_94_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.02364-06"},{"key":"e_1_2_8_95_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2979"},{"key":"e_1_2_8_96_2","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.03145"},{"key":"e_1_2_8_97_2","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2008.47"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1349-7006.2008.01006.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1349-7006.2008.01006.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T09:14:57Z","timestamp":1697188497000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1349-7006.2008.01006.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["10.1111\/j.1349-7006.2008.01006.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1349-7006.2008.01006.x","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}